Ⅲ期可手术乳腺癌新辅助化疗的临床疗效  

Evaluation on clinical effect of neoadjuvant chemotherapy on breast cancer at stage Ⅲ

作　　者：黄河清[1] 章五一[1] 庞倩[1] 

机构地区：[1]广东省农垦中心医院,广东湛江524002

出　　处：《宁夏医学杂志》2006年第8期587-588,共2页Ningxia Medical Journal

摘　　要：目的探讨Ⅲ期可手术乳腺癌新辅助化疗的临床疗效。方法将60例Ⅲ期可手术乳腺癌随机分为新辅助化疗组和对照组。新辅助化疗组术前做2周期CTF(CTX+THP+FUDR)化疗,术后补充放疗、化疗;对照组除不做术前化疗外,手术及其它治疗相同。结果新辅助化疗组临床有效率达76.66%,术后病理肿瘤细胞出现变性、坏死。两组腋窝淋巴结转移阳性率分别为60.52%和79.67%(P<0.01);5年生存率和无病生存率分别为66.66%、50.00%和40.00%、23.33%(P<0.05)。结论新辅助化疗可提高Ⅲ期可手术乳腺癌的临床疗效。Objective To evaluate the clinical efficacy of the neoadjuvant chemytherapy （NACT） for operable stage Ⅲ breast cancer. Methods 60 patients with operable stage Ⅲ breast cancer were randomly divided into two groups the neoadiuvant chemyotherapy （NACT） group and the control group.The NACT group received a chemotherapy with the regimen of （CTX ＋ THP＋ FUDR） for three cycles before operatiom. The two groups received the same operation and postrative adjuvant radio - chemotherapy. Results The clinical response rate in NACT group was 76.66 %. Tumor cues in pathological section occur apomorphosis or necrosis postoperation. The nymph node transfer rate of the two groups is60.52% and 79.67% respectively（ P 〈0.01）.The 5- year survival rates （SYSR） and diseased free survival rate were 66.66% and 50.00% for theNACTgroup, 40.00% and23.33% for the control group （ P 〈0.05）.Conclusion It is suggested that NACTis clinically effective for operable stage Ⅲ breast cancer.

关 键 词：乳腺癌 化疗 临床疗效 

分 类 号：R737.9[医药卫生—肿瘤]